ArticleClinical rheumatology2022
Psoriatic arthritis with hyperuricemia: more peripheral, destructive, and challenging to treat.
Article in Clinical rheumatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 21 citations in OpenAlex.
- Transforming Psoriasis Care: Probiotics and Prebiotics as Novel Therapeutic Approaches.International journal of molecular sciences · 2023Trial
- The Role of Musculoskeletal Ultrasound in Psoriatic Arthritis: From Preclinical Detection to Treatment Monitoring.Current rheumatology reports · 2026Review
- Pro-Inflammatory Synergy Between IL-17, IL-1 and Hyperuricemia in Psoriatic Arthritis: Clinical Implications of a Pilot Study.Diseases (Basel, Switzerland) · 2026Article
- Hyperuricemia in psoriatic arthritis: clinical correlations and implications.Clinical rheumatology · 2025Article
- Gout, Hyperuricemia and Psoriatic Arthritis: An Evolving Conundrum.Current rheumatology reports · 2025Review
- Refractory psoriatic arthritis: emerging concepts in whole process management.Clinical rheumatology · 2025Review
- The effect of calcium oxalate stones and uric acid stones on male sexual function.International urology and nephrology · 2025Article
- Understanding the interplay between psoriatic arthritis and gout: "Psout".Rheumatology international · 2024Review
- Interest in daily clinical practice of screening for gouty disease in patients with psoriatic arthritis.Rheumatology advances in practice · 2024Article
- Impact of hyperuricaemia on patients with psoriatic arthritis treated with secukinumab in the FUTURE 2-5 and MAXIMISE studies.RMD open · 2023Article
- A Comparison of Clinical Characteristics in Overweight/Obese and Normal Weight Patients with Psoriasis Vulgaris: A Bicentric Retrospective Observational Study.Clinical, cosmetic and investigational dermatology · 2023Article
- Acute joint swelling in psoriatic arthritis: Flare or "psout"-A 10-year-monocentric study on synovial fluid.Experimental biology and medicine (Maywood, N.J.) · 2022Article
- A glance into the future of gout.Therapeutic advances in musculoskeletal disease · 2022Review
- Metabolic and Inflammatory Disorders-Main Influencers of Psoriatic Arthritis Activity.Current health sciences journalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo study the impact of hyperuricemia on clinical presentation, severity, and associated comorbidities of psoriatic arthritis (PsA).
methodsRetrospective bicentric case-control study performed in Strasbourg and Colmar, France, from 2009 to 2019. Patients with PsA (according to ICD-10 coding) and at least one available serum urate (SU) measurement were included. Demographic, comorbidities, clinical, and radiographic data were collected. Hyperuricemia was defined as SU level ≥ 360 µmol/L.
resultsWe included 242 patients: 73 (30.2%) had hyperuricemia and 15 (6.2%) met 2015 ACR/EULAR criteria for gout. On univariate analysis, as compared with normo-uricemic patients, hyperuricemic patients were more frequently male (72.6% vs 39.1%, p = 1.6 × 10
conclusionPatients with hyperuricemic PsA show poorer response to PsA treatment and have more peripheral and destructive joint damage than normo-uricemic patients. Key Points • Gout and psoriatic arthritis (PsA) can co-exist in the same patient. • Monosodium urate crystals might have a deleterious impact on PsA. • Hyperuricemic PsA is more polyarticular, less frequently axial, and more destructive than normo-uricemic PsA. • PsA with hyperuricemia should lead to more personalized medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.